Table 2:
Characteristics of New Trials of Adequate Dose and Duration Evidence-Based Medications for PTSD, with aligned PCL Measurement, including start dates from October 1, 2016 through March 7, 2018
| Number of AMTs Aligned with PCL Measurement Patients Contribute | |
| 1, %(n) | 94.2 (786) |
| 2, %(n) | 5.8 (48) |
| Number of Prior AMTs since October 1, 1999 (with or without PCL) | |
| 0, %(n) | 81.1 (676) |
| 1, %(n) | 15.0 (125) |
| 2+, %(n) | 4.0 (33) |
| Number of Prior Adequate PE or CPT Trials since October 1, 1999 (with or without PCL) | |
| 0, %(n) | 93.2 (777) |
| 1, %(n) | 6.2 (52) |
| 2+, %(n) | 0.6 (5) |
| Days from First Available PTSD Diagnosis to Baseline PCL, M (SD) | 1,074.6 (1,378.7) |
| Days from Baseline PCL to Follow-Up PCL, M (SD) | 80.8 (10.3) |
| Baseline PCL Score, M (SD) | 57.8 (11.1) |
Abbreviations. PTSD=posttraumatic stress disorder, PCL=PTSD Checklist, FY=Fiscal Year, AMT=Adequate Medication Trial (12 or more weeks of fluoxetine, sertraline, topiramate, paroxetine, or venlafaxine at required dose at a minimally adequate dose), PE=Prolonged Exposure, CPT=Cognitive Processing Therapy